/Investor DB

Dolby Family Ventures — 2017 Investments

6 investments dated 2017 · listed companies and verified rows first · show all

Iterum Therapeuticsiterumtx.comSeries B · May 2017 · $65M

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesAdvent Life SciencesFrazier Life SciencesSofinnova Venture Partners

Keyssakeyssa.comAug 2017

Keyssa develops a tiny solid-state wireless connector that uses electromagnetic and materials technology to transfer data at up to 6 Gbits per second between devices without software drivers or setup.

Deep TechHardwareSemiconductorsCampbell, US

Eric Almgren(Executive Officer, Director)Gordon Almquist(Executive Officer)

BoardAnthony Fadell(Director)Rahul Chaturvedi(Director)Surendra Mandava(Director)Don McKinney(Director)

Co-investorsIn-Q-TelSamsung Catalyst FundAlsop Louie PartnersIntel CapitalNeuberger Berman

Lightformlightform.comin𝕏Seed · Nov 2017 · $5M

Lightform develops design tools for projected augmented reality, combining computer vision and hardware to enable interactive visual experiences.

AI & Machine LearningDeep TechDeveloper ToolsHardware

Co-investorsComet LabsGen CapitalPresence CapitalTuesday CapitalAnorak VenturesLevensohn Venture Partners+2 more

M3m3db.ioNov 2017 · $15.2M

M3 is an open source metrics platform, originally developed by Uber's Observability team in 2014, built around a purpose-built time series database (M3DB), a query engine, and ingestion/aggregation components.

Cloud ComputingData & InfrastructureDeveloper Tools

Co-investorsCardinia Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Entasis TherapeuticsM3 Biotechnology

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.